There are three ways to look at House Majority Leader Eric Cantor‘s (R) stunning primary defeat Tuesday in VA-07: short-term, medium-term, and long-term. We’ve tried them all in the last few hours.
— In the short run, Republican incumbents are going to get jumpy. There just isn’t as much safety in “safe seats” anymore. Cantor may be just the second incumbent to go down, but as we’ve noted earlier, members are finishing below 60% in their primaries with increasing frequency. (While everyone was watching Mississippi last week, for example, Rep. Leonard Lance (R-NJ) quietly won his primary by just 8 points.) Rep. Doug Lamborn (R-CO) is one of several incumbents in upcoming primaries who’ve had past primary struggles; look for an uptick in activity from them to avoid becoming the next big surprise as Cantor gets their attention.
— In the medium term, nervous incumbents probably means legislating will probably be a quiet business the rest of the year, and maybe beyond for the House GOP majority. Especially given Dave Brat‘s (R) focus on immigration, any movement on that issue looks especially unlikely (even though Senate “Gang of 8” co-author Lindsey Graham (R) breezed through his SC primary Tuesday).
— It’s difficult to ascribe potential long-term effects to a single House primary, though the first-ever primary defeat for a House majority leader will ripple the pond more than most. The situation points to a disconnect between true “tea party” grassroots energy and the national “tea party” groups that didn’t glance twice at this race (but will probably raise lots of money off Brat’s victory). And the punishment doled out to Cantor for not remaining in touch with his grassroots base highlights a looming issue for 2016 presidential candidates who are already spending a lot of energy wooing big-money donors.
This doesn’t even get into the internal politics of replacing Cantor (and possibly others) in House GOP leadership. But his defeat has implications throughout national politics.
— Scott Bland
- 1 The Story of 2016: Republicans Feeling “Betrayed” by Their Leaders
- 2 How Washington Derailed Amtrak
- 3 Hillary Clinton Won (But It Won’t Always Be This Way)
- 4 The Number of U.S. Farmers Markets Has Nearly Doubled in the Last Five Years
- 5 Army Lt. Gen. Sean MacFarland to Lead U.S. Fight Against ISIS
What We're Following See More »
In a release Tuesday afternoon, the White House announced that President Obama has commuted and/or reduced the sentences of another 111 convicted criminals, mostly convicted of drug possession or trafficking. About 35 were serving life sentences.
Senate Judiciary Committee Chairman Chuck Grassley (R-IA) said Monday he'd now be willing to hold a hearing on Supreme Court nominee Merrick Garland in a lame-duck session of Congress. While he said he wouldn't push for it, he said if "Hillary Clinton wins the White House, and a majority of senators convinced him to do so," he would soften his previous opposition.
In a new Monmouth University poll, 46% of likely voters support Clinton and 39% back Trump, with 7% supporting Libertarian Gary Johnson, and 2% backing Jill Stein of the Green Party. That's down from a poll taken right after the Democratic convention, in which Clinton led by 13 points.
“Hillary Clinton’s advisers are talking to Donald J. Trump’s ghostwriter of The Art of the Deal, seeking insights about Mr. Trump’s deepest insecurities as they devise strategies to needle and undermine him in four weeks at the first presidential debate, the most anticipated in a generation. ... Her team is also getting advice from psychology experts to help create a personality profile of Mr. Trump to gauge how he may respond to attacks and deal with a woman as his sole adversary on the debate stage.”
The House Committee on Oversight and Government Reform has requested documents from the CEO of Mylan, "the pharmaceutical company under fire after raising the price of EpiPens more than 400 percent since 2007." Meanwhile, top members of the Energy and Commerce Committee are pressing the FDA on the lack of generic competition for EpiPens.